Supplementary Table 1. Clinimetric used in the study.

Name	**Formula and meaning**
Amyotrophic Lateral Sclerosis Functional Rating Scale Revised score (ALSFRS_R)	A composite functional outcome measure widely used in clinical trials and biomarker studies in ALS ranging from 0 (maximum disability) to 48 (normal neurological functioning).
Symptom onset	The time of the earliest reported symptoms, including muscle cramps, fasciculation, weakness and speech changes
Diagnostic latency	The time interval between symptoms onset and the diagnosis, expressed in months.
Disease duration at baseline	The time interval from symptoms onset to the baseline sampling, expressed in months.
Progression rate at baseline (PRB)	(48 minus the ALSFRS_R score at baseline)/duration in months between symptoms onset and baseline.
Progression Rate at the last visit (PRL)	The progression rate with reference to the last visit/assessment in the study. In this study, patients with PRL>1.0, 0.5-1.0, and <0.5 are defined as ALS-Fast, ALS-Intermediate and ALS-Slow, respectively.
ALSFRS_R slope	ALSFRS_R score at 2^{nd} visit minus ALSFRS_R score at 1^{st} visit / time between visits. It is used to define the disease progression between two consecutive visits. A negative value indicates deterioration in function.